Evolution of fibrosis during HCV recurrence after liver transplantation - Influence of IL-28B SNP and response to peg-IFN and ribavirin treatment

Journal of Viral Hepatitis

Volumn 20, Issue 11, 2013, Pages 770-778

  Ackefors, M ^a   Nystrom J ^a   Wernerson, A ^a   Gjertsen, H ^b   Sonnerborg A ^a   Weiland, O ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

hepatitis C virus; IL 28B; liver transplantation; peg IFN; ribavirin

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; ELASTICITY; FEMALE; FOLLOW UP; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

HEPATITIS C VIRUS; IL-28B; LIVER TRANSPLANTATION; PEG-IFN; RIBAVIRIN;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECURRENCE; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84885443550     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12099     Document Type: Article

References (24)

1. Berenguer M,. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49 (2): 274-287.
2. Gjertsen H, Weiland O, Oksanen A, Soderdahl G, Broome U, Ericzon BG,. Liver transplantation for HCV cirrhosis at Karolinska University Hospital Huddinge, Stockholm. Transplant Proc 2006; 38 (8): 2675-2676. (Pubitemid 44693657)
3. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122 (4): 889-896. (Pubitemid 34267271)
4. Gane EJ, Portmann BC, Naoumov NV, et al,. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334 (13): 815-820. (Pubitemid 26099603)
5. Melum E, Friman S, Bjoro K, et al,. Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma. J Hepatol 2007; 47 (6): 777-783. (Pubitemid 350051112)
6. Ackefors M, Wernerson A, Gjertsen H, Weiland O,. Concentration guided ribavirin dosing with darbepoetin support and Peg-IFN alfa-2a for treatment of hepatitis C recurrence after Liver transplantation. J Viral Hepat 2012; 19: 635-639.
7. Hornfeldt E, Gjertsen H, Weiland O,. High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation. Scand J Infect Dis 2008; 40 (3): 259-265. (Pubitemid 351260436)
8. Terrault NA, Berenguer M,. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12 (8): 1192-1204. (Pubitemid 44194586)
9. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13): 975-982.
10. Hadziyannis SJ, Sette H Jr, Morgan TR, et al,. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140 (5): 346-355.
11. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965. (Pubitemid 32913521)
12. Berg T,. Tailored treatment for hepatitis C. Clin Liver Dis 2008; 12 (3): 507-528. (Pubitemid 351952467)
13. Berenguer M, Aguilera V, Rubin A, Ortiz C, Jimenez M, Prieto M,. Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. J Hepatol 2012; 56 (6): 1310-1316.
14. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262): 399-401.
15. Thomas DL, Thio CL, Martin MP, et al,. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461 (7265): 798-801.
16. Lange CM, Moradpour D, Doehring A, et al,. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011; 55 (2): 322-327.
17. Charlton MR, Thompson A, Veldt BJ, et al,. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53 (1): 317-324.
18. Fukuhara T, Taketomi A, Motomura T, et al,. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139 (5): 1577-1585.
19. Batts KP, Ludwig J,. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19 (12): 1409-1417.
20. Castera L, Forns X, Alberti A,. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48 (5): 835-847.
21. Bahra M, Jacob D, Neumann UP, et al,. Influence of donor histology on outcome in patients undergoing transplantation for hepatitis C. Transplantation 2007; 84 (2): 144-148. (Pubitemid 47205746)
22. Ydreborg M, Westin J, Lagging M, Castedal M, Friman S,. Impact of donor histology on survival following liver transplantation for chronic hepatitis C virus infection: a Scandinavian single-center experience. Scand J Gastroenterol 2012; 47: 710-717.
23. Myers RP, Patel K, Pianko S, Poynard T, McHutchison JG,. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J Viral Hepat 2003; 10 (1): 16-22. (Pubitemid 36237807)
24. Neumann UP, Berg T, Bahra M, et al,. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41 (5): 830-836. (Pubitemid 39434314)